Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01289431 · ClinicalTrials.gov registry record · Phase 2
Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis
A Phase 2 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 236
- Enrollment target
NCT01289431 is a Phase 2 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 236 participants.
The verdict
NCT01289431, a Phase 2 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 236 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the dose response, and efficacy of Mapracorat ophthalmic formulation compared to its vehicle for the prevention of symptoms and signs associated with allergic conjunctivitis using a conjunctival allergen challenge (CAC) model.
Interventions
- DRUG Vehicle
- DRUG Mapracorat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 236 participants |
| Start Date | 2011-02 |
| Est. Completion | 2011-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01289431
The ClinicalTrials.gov registry entry for NCT01289431 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 236 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT01289431 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01289431 about?
NCT01289431 is a clinical study titled "Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis". The objective of this study is to evaluate the dose response, and efficacy of Mapracorat ophthalmic formulation compared to its vehicle for the prevention of symptoms and signs associated with allergic conjunctivitis using a conjunctival allergen challenge (CAC) model.
What is the current status of trial NCT01289431?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 236 participants. The study started on 2011-02. Estimated completion is 2011-04.
What interventions are being tested in trial NCT01289431?
The interventions under investigation include: Vehicle (DRUG), Mapracorat (DRUG).
Who is sponsoring clinical trial NCT01289431?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.